---
schema_version: "secwatch.filing_event.v1"
accession: "0000320017-24-000049"
form_type: "8-K"
ticker: "LSTA"
cik: "0000320017"
company_name: "LISATA THERAPEUTICS, INC."
filed_at: "2024-08-12T23:59:59+00:00"
generated_at: "2026-05-31T10:12:02.386059+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lisata Therapeutics Q2 2024 net loss $5.0M; ASCEND Phase 2b top-line data expected Q4 2024

## Summary
- Net loss $5.0M in Q2 2024 vs $4.0M in Q2 2023; operating expenses down 19.7% to $5.5M.
- Cash & equivalents $38.3M; funding into early 2026 covering all active trials to data milestones.
- Phase 2b ASCEND trial (certepetide + chemo in mPDAC) top-line results from 95-patient Cohort A on track for Q4 2024.
- BOLSTER Phase 2a in 1L cholangiocarcinoma fully enrolled ahead of plan; topline data mid-2025; 2L cohort added.
- Certepetide received U.S. FDA Orphan Drug and Rare Pediatric Disease designations for osteosarcoma in H1 2024.

## SEC filing metadata
- accession: 0000320017-24-000049
- form_type: 8-K
- ticker: LSTA
- cik: 0000320017
- company_name: LISATA THERAPEUTICS, INC.
- filed_at: 2024-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/320017/000032001724000049/0000320017-24-000049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/320017/000032001724000049/clbs-20240812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000320017-24-000049
- JSON: https://secwatch.observer/filing/0000320017-24-000049.json
- Plain text: https://secwatch.observer/filing/0000320017-24-000049.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.